For research use only. Not for therapeutic Use.
Cavosonstat (N91115) is an orally active S-nitrosoglutathione reductase (GSNOR) inhibitor. Cavosonstat is a CFTR stabilizer, and can be used for cystic fibrosis research[1].
Cavosonstat (N91115), a CFTR modulator, promotes cystic fibrosis transmembrane conductance regulator (CFTR) maturation and plasma membrane stability, with a mechanism of action complementary to CFTR correctors and potentiators[1].
| Catalog Number | I005689 |
| CAS Number | 1371587-51-7 |
| Synonyms | 3-chloro-4-(6-hydroxyquinolin-2-yl)benzoic acid |
| Molecular Formula | C16H10ClNO3 |
| Purity | ≥95% |
| InChI | InChI=1S/C16H10ClNO3/c17-13-8-10(16(20)21)1-4-12(13)15-5-2-9-7-11(19)3-6-14(9)18-15/h1-8,19H,(H,20,21) |
| InChIKey | BXSZILNGNMDGSL-UHFFFAOYSA-N |
| SMILES | C1=CC(=C(C=C1C(=O)O)Cl)C2=NC3=C(C=C2)C=C(C=C3)O |
| Reference | [1]. Scott H Donaldson, et al. Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR. J Cyst Fibros. 2017 May;16(3):371-379. |
